JPMorgan Chase & Co. Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price objective lowered by research analysts at JPMorgan Chase & Co. from $120.00 to $74.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 246.77% from the stock’s previous close.

Other equities research analysts also recently issued reports about the stock. Guggenheim cut their target price on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating on the stock in a research report on Monday, January 5th. Canaccord Genuity Group decreased their price target on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating for the company in a research report on Wednesday, February 18th. Jefferies Financial Group dropped their price target on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a research note on Tuesday, December 30th. Wedbush reiterated a “neutral” rating and set a $25.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, February 17th. Finally, Bank of America reduced their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, January 2nd. Sixteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $65.76.

Ultragenyx Pharmaceutical Stock Down 1.7%

Shares of RARE opened at $21.34 on Thursday. The stock has a market cap of $2.06 billion, a PE ratio of -3.65 and a beta of 0.16. Ultragenyx Pharmaceutical has a 12-month low of $18.41 and a 12-month high of $42.37. The business has a 50-day simple moving average of $23.01 and a two-hundred day simple moving average of $28.83.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The firm had revenue of $207.28 million for the quarter, compared to analyst estimates of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The business’s revenue for the quarter was up 25.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.39) earnings per share. On average, equities research analysts expect that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 8,409 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.70, for a total value of $190,884.30. Following the transaction, the chief financial officer directly owned 86,669 shares of the company’s stock, valued at $1,967,386.30. The trade was a 8.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider John Richard Pinion sold 10,029 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $228,661.20. Following the sale, the insider owned 110,026 shares in the company, valued at approximately $2,508,592.80. The trade was a 8.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 104,958 shares of company stock worth $2,394,858. Corporate insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently modified their holdings of the business. Jacobs Levy Equity Management Inc. lifted its position in shares of Ultragenyx Pharmaceutical by 614.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock valued at $65,205,000 after acquiring an additional 1,864,164 shares during the period. Norges Bank acquired a new stake in Ultragenyx Pharmaceutical in the fourth quarter worth $29,004,000. Millennium Management LLC increased its stake in Ultragenyx Pharmaceutical by 787.6% in the fourth quarter. Millennium Management LLC now owns 880,644 shares of the biopharmaceutical company’s stock valued at $20,255,000 after purchasing an additional 781,431 shares in the last quarter. Vestal Point Capital LP bought a new stake in Ultragenyx Pharmaceutical in the third quarter valued at $22,560,000. Finally, Russell Investments Group Ltd. raised its holdings in shares of Ultragenyx Pharmaceutical by 599.2% during the third quarter. Russell Investments Group Ltd. now owns 840,451 shares of the biopharmaceutical company’s stock valued at $25,281,000 after purchasing an additional 720,256 shares during the period. 97.67% of the stock is currently owned by institutional investors.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Phase‑3 win for DTX301 (OTC deficiency): Ultragenyx reported that its AAV8 gene therapy (DTX301) reduced ammonia ~18% versus placebo and maintained normal ammonia through 36 weeks in a late‑stage trial—an important efficacy readout that advances the program toward potential regulatory/commercial milestones. Read More.
• Neutral Sentiment: JPMorgan cuts price target but keeps an Overweight rating: JPMorgan lowered its target from $120 to $74 while maintaining an Overweight stance—reducing near‑term upside expectations but still signaling conviction in the company’s longer‑term potential relative to peers. Read More.
• Negative Sentiment: Multiple securities‑fraud class action notices and lead‑plaintiff deadlines: Several law firms and investor‑alert services (Schall, Robbins Geller, Faruqi, Rosen, Pomerantz, DJS, ClaimsFiler, etc.) have announced a securities class action covering purchases from Aug 3, 2023–Dec 26, 2025 and are soliciting lead‑plaintiff candidates (April 6, 2026 deadline). This increases legal and headline risk, can pressure the stock near term, and may create potential future liabilities. Read More.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.